Protagonist Therapeutics, Inc. – NASDAQ:PTGX
Protagonist Therapeutics stock price today
$56.2
+17.24
+44.25%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Protagonist Therapeutics stock price monthly change
+7.86%
month
Protagonist Therapeutics stock price quarterly change
+7.86%
quarter
Protagonist Therapeutics stock price yearly change
+66.21%
year
Protagonist Therapeutics key metrics
Market Cap | 2.40B |
Enterprise value | 777.34M |
P/E | -8.73 |
EV/Sales | 29.24 |
EV/EBITDA | -4.21 |
Price/Sales | 33.83 |
Price/Book | 4.17 |
PEG ratio | -2.15 |
EPS | 2.6 |
Revenue | N/A |
EBITDA | 151.15M |
Income | 162.11M |
Revenue Q/Q | N/A |
Revenue Y/Y | 36565.07% |
Profit margin | -712.39% |
Oper. margin | -729.57% |
Gross margin | 3.23% |
EBIT margin | -729.57% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProtagonist Therapeutics stock price history
Protagonist Therapeutics stock forecast
Protagonist Therapeutics financial statements
Average Price Target
$57.33
Potential upside: 2.01%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -38.46M | |
|---|---|---|---|
| Sep 2023 | 0 | -34.10M | |
| Dec 2023 | 60M | 27.33M | 45.56% |
| Mar 2024 | 254.95M | 207.34M | 81.32% |
| Jun 2023 | 320466000 | 26.39M | 8.24% |
|---|---|---|---|
| Sep 2023 | 330016000 | 27.86M | 8.44% |
| Dec 2023 | 357951000 | 21.27M | 5.94% |
| Mar 2024 | 629276000 | 68.83M | 10.94% |
| Jun 2023 | -26.23M | 25.76M | 108.17M |
|---|---|---|---|
| Sep 2023 | -26.61M | -13.55M | 35.31M |
| Dec 2023 | 16.96M | -61.28M | 527K |
| Mar 2024 | -27.42M | 6.07M | 7.19M |
Protagonist Therapeutics alternative data
| Aug 2023 | 103 |
|---|---|
| Sep 2023 | 106 |
| Oct 2023 | 106 |
| Nov 2023 | 106 |
| Dec 2023 | 111 |
| Jan 2024 | 111 |
| Feb 2024 | 111 |
| Mar 2024 | 112 |
| Apr 2024 | 112 |
| May 2024 | 112 |
| Jun 2024 | 124 |
| Jul 2024 | 124 |
Protagonist Therapeutics other data
100.00%
0.00%
of PTGX is owned by hedge funds
137
-10
50.64M
+1.20M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 75000 |
| Jan 2024 | 0 | 5000 |
| Feb 2024 | 0 | 9939 |
| Mar 2024 | 0 | 57223 |
| Apr 2024 | 0 | 26234 |
| Jun 2024 | 0 | 43000 |
| Jul 2024 | 0 | 8000 |
| Sep 2024 | 0 | 22203 |
| Nov 2024 | 0 | 256063 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MOLINA ARTURO MD officer: Chief Medical Officer | Stock Option (right to buy) | 10,000 | $8.04 | $80,400 | ||
Option | MOLINA ARTURO MD officer: Chief Medical Officer | Stock Option (right to buy) | 16,000 | $8.04 | $128,640 | ||
Option | MOLINA ARTURO MD officer: Chief Medical Officer | Common Stock | 16,000 | $8.04 | $128,640 | ||
Option | MOLINA ARTURO MD officer: Chief Medical Officer | Common Stock | 10,000 | $8.04 | $80,400 | ||
Sale | MOLINA ARTURO MD officer: Chief Medical Officer | Common Stock | 26,000 | $44.67 | $1,161,290 | ||
Option | MOLINA ARTURO MD officer: Chief Medical Officer | Stock Option (right to buy) | 5,529 | $8.04 | $44,453 | ||
Option | MOLINA ARTURO MD officer: Chief Medical Officer | Common Stock | 5,529 | $8.04 | $44,453 | ||
Sale | MOLINA ARTURO MD officer: Chief Medical Officer | Common Stock | 5,529 | $45.6 | $252,122 | ||
Option | GUPTA SUNEEL officer: Chief De.. | Common Stock | 30,000 | $12.17 | $365,100 | ||
Option | GUPTA SUNEEL officer: Chief De.. | Common Stock | 450 | $12.17 | $5,477 |
| Patent |
|---|
Application Filling date: 13 Dec 2021 Issue date: 11 Aug 2022 |
Application Filling date: 27 Mar 2020 Issue date: 16 Jun 2022 |
Application Filling date: 19 Nov 2021 Issue date: 9 Jun 2022 |
Application Filling date: 7 May 2021 Issue date: 10 Feb 2022 |
Application Filling date: 29 Dec 2020 Issue date: 2 Dec 2021 |
Application ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES Filling date: 28 Jan 2021 Issue date: 25 Nov 2021 |
Application Filling date: 14 Jan 2021 Issue date: 26 Aug 2021 |
Grant Filling date: 24 Aug 2020 Issue date: 22 Jun 2021 |
Application Filling date: 1 Oct 2020 Issue date: 20 May 2021 |
Grant Utility: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Filling date: 12 Dec 2018 Issue date: 9 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2020 10 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q1 2020 13 May 2020 | Q1 2020 Earnings Call Transcript |
| Q4 2019 10 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Q4 2018 13 Mar 2019 | Q4 2018 Earnings Call Transcript |
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
Protagonist Therapeutics: There Are Reasons Behind Johnson & Johnson's Optimism
Protagonist Therapeutics: Evaluating Rusfertide's Potential For PV
Protagonist: Rusfertide Has Potential For Patients With Polycythemia Vera
Protagonist Therapeutics Sees Steady If Bumpy Progress
Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023
Biopharma Exposure In SVB Financial Group And Investor Strategy
Protagonist Therapeutics: More Good News Likely To Come
Protagonist: Too Many Red Flags
-
What's the price of Protagonist Therapeutics stock today?
One share of Protagonist Therapeutics stock can currently be purchased for approximately $56.2.
-
When is Protagonist Therapeutics's next earnings date?
Unfortunately, Protagonist Therapeutics's (PTGX) next earnings date is currently unknown.
-
Does Protagonist Therapeutics pay dividends?
No, Protagonist Therapeutics does not pay dividends.
-
How much money does Protagonist Therapeutics make?
Protagonist Therapeutics has a market capitalization of 2.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 125.73% to 60M US dollars.
-
What is Protagonist Therapeutics's stock symbol?
Protagonist Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PTGX".
-
What is Protagonist Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Protagonist Therapeutics?
Shares of Protagonist Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Protagonist Therapeutics's key executives?
Protagonist Therapeutics's management team includes the following people:
- Dr. Dinesh V. Patel Ph.D. Chief Executive Officer, Pres, Interim PAO, Sec. & Director(age: 68, pay: $1,040,000)
- Dr. David Y. Liu Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel.(age: 75, pay: $719,420)
- Dr. Suneel K. Gupta Ph.D. Chief Devel. Officer(age: 67, pay: $680,320)
-
How many employees does Protagonist Therapeutics have?
As Jul 2024, Protagonist Therapeutics employs 124 workers, which is 11% more then previous quarter.
-
When Protagonist Therapeutics went public?
Protagonist Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 11 Aug 2016.
-
What is Protagonist Therapeutics's official website?
The official website for Protagonist Therapeutics is protagonist-inc.com.
-
Where are Protagonist Therapeutics's headquarters?
Protagonist Therapeutics is headquartered at 7707 Gateway Boulevard, Newark, CA.
-
How can i contact Protagonist Therapeutics?
Protagonist Therapeutics's mailing address is 7707 Gateway Boulevard, Newark, CA and company can be reached via phone at +51 04740170.
-
What is Protagonist Therapeutics stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Protagonist Therapeutics in the last 12 months, the avarage price target is $57.33. The average price target represents a 2.01% change from the last price of $56.2.
Protagonist Therapeutics company profile:
Protagonist Therapeutics, Inc.
protagonist-inc.comExchange:
NASDAQ
Full time employees:
126
Industry:
Biotechnology
Sector:
Healthcare
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
7707 Gateway Boulevard
Newark, CA 94560-1160
Newark, CA 94560-1160
CIK: 0001377121
ISIN: US74366E1029
CUSIP: 74366E102
